Indian Immunodiagnostics Market to Reach US$ 264 Million by 2016

Noida, India (PressExposure) March 05, 2012 -- IMARC Group, one of the world's leading research and advisory firms, in its latest report "Indian Diagnostic & Therapeutic Antibodies Market Report & Forecast: 2011-2016" finds that the Indian Immunodiagnostics market is expected to grow robustly in the coming years and reach revenues worth INR 11,881 million (US$ 264 million) by 2016. The study, that has been undertaken using desk-based as well as qualitative primary market research provides and draws upon a comprehensive analysis of the Indian Immunodiagnostics market.

Key Segments Analyzed

Understanding the strengths, weaknesses, opportunities and challenges in the Indian Immunodiagnostics market

Understanding the technological considerations and regulatory factors in the Indian Immunodiagnostics market

• Evaluating the various types of Immunodiagnostic tests conducted in India and analyzing their strengths and weaknesses

• Understanding the key regulations for registering, manufacturing and importing diagnostics in India

Comprehensive situation analysis of the Indian Immunodiagnostics market

Segments covered: HIV, Hepatitis B, Hepatitis C, Tuberculosis, Dengue, Syphilis and Cancer

Focus of the analysis in each segment:

• Number of tests conducted each year

• Breakup by type of tests conducted

• Current and future market sales

• Average cost of diagnostic tests

• Key players operating in the market

Key Questions Answered in this Report:

• What is the current size and growth of the Indian Immunodiagnostics market?

• What are the most popular types of Immunodiagnostic tests conducted in India?

• What are the most popular indications for which Immunodiagnostic tests are conducted?

• Who are the key players operating in the Indian Immunodiagnostics market?

• What are the various regulations in the Indian Immunodiagnostics market?

• What are the strengths, weaknesses, opportunities and threats in the Indian Immunodiagnostics Market?

• What is the prevalence of Elisa and Rapid tests for each Indication?

• What is the future of Immunodiagnostics in India?

• What is the current and future landscape of HIV diagnostics in India?

• What is the current and future landscape of Hepatitis B diagnostics in India?

• What is the current and future landscape of Hepatitis C diagnostics in India?

• What is the current and future landscape of Tuberculosis diagnostics in India?

• What is the current and future landscape of Dengue diagnostics in India?

• What is the current and future landscape of Syphilis diagnostics in India?

• What is the current and future landscape of Cancer diagnostics in India?

To obtain the complete report, please contact:

IMARC Group Asia

Email: apac@imarcgroup.com

Phone: +91-120-425-6531

IMARC Group North America

Email: america@imarcgroup.com

Phone: +1-631-791-1145

To know more please visit: http://www.imarcgroup.com/indian-diagnostic-therapeutic-antibodies-market-report-forecast-2011-2016-2/

About IMARC Group

Imarc Group is one of the world's leading providers of lifescience market intelligence. Our award winning and trusted portfolio of proprietary business solutions have been supporting some of the world's leading pharmaceutical companies, biotechnology companies, medical device companies, clinical research organizations, contract manufacturers and hospitals for over 6 years. We have helped organizations in achieving peak performance, maintaining their leadership positions and raising them to the next level.

Press Release Source: http://PressExposure.com/PR/IMARC_Group.html

Press Release Submitted On: March 05, 2012 at 4:53 am
This article has been viewed 66578 time(s).